TickerFacts.

Company research / TECH

Bio-Techne Corp (TECH)

Build a valuation ↗↓ Download CSV

SEC name BIO-TECHNE Corp · CIK 0000842023 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated MN
  • Fiscal year ends Jun 30

For the year ended 2026-06-30, Bio-Techne Corp reported revenue of $1.22B. Revenue fell 0.4% from the prior annual period.

Key ratios (year ended 2026-06-30)

65.8%
Gross margin
20.7%
Operating margin
15.0%
Net margin
8.6%
Return on year-end equity
-0.4%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-09-30

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

Stock splits: 4-for-1, first reflected in a filing dated 2023-02-07. Figures are as filed: per-share figures and share counts last reported before a split are on the old share basis, so changes and growth rates across a split are not shown. Splits are read from the filings' own restatements, so a share conversion in a merger or reorganization shows up the same way.

Period ended2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-30
Revenue$1.22B$1.22B$1.16B$1.14B$1.11B$931.03M$738.69M$714.01M$642.99M$563.00M
Cost of Revenue$415.97M$429.36M$389.33M$366.89M$349.10M$298.18M$255.50M$240.51M$210.85M$188.46M
Gross Profit$799.07M$790.27M$769.73M$769.82M$756.50M$632.85M$483.19M$473.49M$432.14M$374.54M
R&D Expense$94.77M$99.50M$96.66M$92.49M$87.14M$70.60M$65.19M$62.41M$55.33M$53.51M
Operating Income$251.89M$102.25M$206.69M$298.94M$296.59M$237.30M$157.42M$146.72M$136.18M$120.58M
Depreciation & Amortization$97.36M$109.90M$111.71M$107.24M$101.07M$87.75M$82.74M$78.17M$64.46M$60.04M
EBITDA$349.25M$212.16M$318.40M$406.18M$397.66M$325.04M$240.16M$224.89M$200.64M$180.62M
Net Income$181.86M$73.40M$168.10M$285.44M$263.10M$139.59M$229.30M$96.07M$126.15M$76.09M
EPS (Diluted)$1.16$0.46$1.05$1.76$1.66$0.87$5.82$2.47$3.31$2.03
Total Assets$2.59B$2.56B$2.70B$2.64B$2.29B$2.26B$2.03B$1.88B$1.59B$1.56B
Shareholders' Equity$2.11B$1.92B$2.07B$1.97B$1.70B$1.56B$1.38B$1.17B$1.08B$949.63M
Cash & Equivalents$264.71M$162.19M$151.79M$180.57M$172.57M$199.09M$146.62M$100.89M$121.99M$91.61M
Operating Cash Flow$292.07M$287.56M$298.98M$254.39M$325.27M$352.16M$205.22M$181.62M$170.37M$143.72M
Capital Expenditures$28.85M$31.01M$62.88M$38.24M$44.91M$44.30M$51.74M$25.41M$20.93M$15.18M
Free Cash Flow$263.22M$256.55M$236.10M$216.15M$280.36M$307.86M$153.47M$156.21M$149.43M$128.54M
Share Repurchases$41.67M$275.73M$80.04M$19.56M$160.95M$43.18M$50.11M$15.40M$0n/a
Dividends Paid$49.92M$50.39M$50.42M$50.28M$50.19M$49.62M$48.90M$48.36M$47.97M$47.33M
Shares Outstanding156.10M154.97M158.22M157.64M156.64M38.96M38.45M37.93M37.61M37.36M
Dividends Per Share$0.32$0.32$0.32$0.32$0.32$0.32$1.28$1.28$1.28$1.28
Weighted Average Diluted Shares157.01M159.72M160.77M161.85M164.11M161.93M39.40M38.89M38.05M37.50M
EPS (Basic)$1.17$0.47$1.07$1.81$1.73$0.91$6.00$2.54$3.36$2.04

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView